ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,621Medicare Part D Prescriptions Filled, Including Refills

Rank: 353 out of 4623

$507K Total Retail Price of All Prescriptions

Rank: 715 out of 4623

904 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

9% of this provider’s 904 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 9,415 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
LISINOPRIL 579 504 1 4
LEVOTHYROXINE SODIUM 460 404 2 1
SIMVASTATIN 444 390 3 2
METFORMIN HCL 427 360 4 6
OMEPRAZOLE 420 369 5 7
METOPROLOL TARTRATE 398 314 6 9
PRAVASTATIN SODIUM 380 307 7 11
AMLODIPINE BESYLATE 362 307 8 5
FUROSEMIDE 352 291 9 8
CRESTOR 315 274 10 20
HYDROCHLOROTHIAZIDE 269 240 11 10
HYDROCODONE-ACETAMINOPHEN 211 108 S3 12 3
GABAPENTIN 198 144 13 16
ALENDRONATE SODIUM 178 175 14 22
LOVASTATIN 166 145 15 34
ZOLPIDEM TARTRATE 160 120 16 18
VERAPAMIL ER 143 120 17 96
LISINOPRIL-HYDROCHLOROTHIAZIDE 129 122 18 19
METOPROLOL SUCCINATE 123 103 19 13
ATENOLOL 117 92 20 28
CLOPIDOGREL 117 95 20 31
POTASSIUM CHLORIDE 115 103 22 14
ATORVASTATIN CALCIUM 113 94 23 12
GLIMEPIRIDE 112 65 24 38
LIPITOR 109 100 25 100
HYDRALAZINE HCL 104 90 26 99
WARFARIN SODIUM 103 97 27 24
MELOXICAM 98 84 28 27
ALLOPURINOL 90 82 29 37
PLAVIX 88 71 30 45
CARVEDILOL 85 75 31 25
RAMIPRIL 83 80 32 76
ISOSORBIDE MONONITRATE ER 81 76 33 60
NIFEDIPINE ER 77 77 34 97
TRAMADOL HCL 73 49 35 15
CITALOPRAM HBR 73 68 35 23
GLYBURIDE 70 70 R 37 59
CLONIDINE HCL 67 24 38 40
LEVOFLOXACIN 67 58 38 81
NEXIUM 67 41 38 17
DIOVAN HCT 65 58 41 67
DIOVAN 65 52 41 39
ENALAPRIL MALEATE 61 42 43 41
FLUTICASONE PROPIONATE 60 48 44 32
AMLODIPINE BESYLATE-BENAZEPRIL 59 52 45 55
SERTRALINE HCL 58 32 46 26
DONEPEZIL HCL 56 56 47 30
NIASPAN 55 36 48 110
RANITIDINE HCL 53 46 49 47
DIGOXIN 52 52 50 58
TRAZODONE HCL 51 41 51 42
GLIPIZIDE 51 34 51 49
AZITHROMYCIN 50 37 53 33
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 6, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.